Hanmi Pharm (128940) Fundamentals 2026 — P/E 24.6x, Revenue Analysis | SniperIQ
Hanmi Pharm (128940) is a KR-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ₩4.68T, trading at ₩369000.00 on the KSC. This SniperIQ fundamentals page covers Hanmi Pharm's valuation (P/E 24.6x, P/B 4.1x), profitability (net margin 11.1%), revenue (₩1.55T in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hanmi Pharm's market cap?
Hanmi Pharm (128940) has a market capitalization of approximately ₩4.68T, trading at ₩369000.00 on the KSC. Market cap moves with the live share price.
What is Hanmi Pharm's P/E ratio?
Hanmi Pharm's trailing twelve-month P/E ratio is 24.6x, with a price-to-book (P/B) of 4.1x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hanmi Pharm?
Hanmi Pharm runs a net profit margin of 11.1%, a gross margin of 57.3%, and an operating margin of 13.8%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hanmi Pharm generate?
Hanmi Pharm reported revenue of ₩1.55T for fiscal year 2025, with net income of ₩170.5B and earnings per share (EPS) of 13371. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hanmi Pharm pay a dividend?
Hanmi Pharm offers a trailing dividend yield of about 0.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Hanmi Pharm financially healthy?
Hanmi Pharm carries a debt-to-equity ratio of 0.32x and a current ratio of 1.54x, with a market beta of 0.46. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hanmi Pharm a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hanmi Pharm (128940) the key facts are: market cap ₩4.68T, P/E 24.6x, revenue ₩1.55T, 52-week range 267500-647000. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hanmi Pharm's full fundamentals live
Get Hanmi Pharm's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.